AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01653548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habituation Reminder Training
Description: Participants will hear a unique sound after habituating to a personal stressor.
Study NCT01653548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habituation Reminder
Description: Participants will hear the habituation reminder outside of the lab via a cellular phone.
Study NCT01653548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habituation
Description: Participants will habituate to personally-relevant stressor.
Study NCT02562456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART using Fuji IX
Description: Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
Study NCT02562456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
Study NCT01697514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Powder administered orally (may be sprinkled on soft food).
Study NCT03894930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metta meditation
Description: Administered 5 days per week for 8 weeks.
Study NCT02469285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified pork
Description: Pork with modified fatty acid composition
Study NCT02469285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pork
Description: Pork with normal fat composition
Study NCT02469285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pork and berries
Description: Pork with normal fat composition and Finnish berries
Study NCT00500084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Administered orally
Study NCT04057274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise assessment
Description: The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
Study NCT03439865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet PO BID x 14 days
Study NCT03439865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard of care treatment
Description: topical nasal steroid spray and culture-directed antibiotics x 14 days
Study NCT03439865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care treatment
Description: topical nasal steroid spray and culture-directed antibiotics x 14 days
Study NCT00704782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Study NCT03203239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Light (670 nm energy)
Description: Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
Study NCT03203239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octafluoropropane
Description: All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
Study NCT03887897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation
Description: Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope
Study NCT02500524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocamide diethanolamine
Description: Topical lotion
Study NCT02500524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin
Description: Topical creme rinse
Study NCT03452592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alflutinib
Description: Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
Study NCT00183274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d
Study NCT00183274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: six month intervention with placebo drug
Study NCT02756416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI brain
Description: Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
Study NCT02756416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASL-MRI brain
Description: ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
Study NCT02756416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRA brain
Description: MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
Study NCT03017235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution
Description: Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
Study NCT03017235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder
Description: Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
Study NCT02327624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Compare Clopidogrel to two doses of Ticagrelor 60 and 90
Study NCT02327624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60
Description: Compare Clopidogrel to two doses of Ticagrelor 60 and 90
Study NCT02327624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90
Description: Compare Clopidogrel to two doses of Ticagrelor 60 and 90
Study NCT01538654 — intervention group
Intervention type: PROCEDURE
Intervention: enteral protein tube feeding in obese
Description: The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
Study NCT02214238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP device
Study NCT02214238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP device
Study NCT00581113 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
Study NCT04499261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Patients were supine in a reverse Trendelenburg position and received intravenous inhalation combined with anesthesia. The patients' legs were spread apart. A carbon dioxide pneumoperitoneum was established. The intermittent Pringle's maneuver was carried out when necessary. Five trocars were placed in a fan shape around the lesion. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
Study NCT04499261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Patients were placed in the supine position and received intravenous inhalation combined with anesthesia. The intermittent Pringle's maneuver was carried out when necessary. Routinely, a reversed L-shape incision was performed. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
Study NCT01604265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
Study NCT01604265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
Study NCT01578733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein intake.
Description: •Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
Study NCT04363775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The standard Macintosh laryngoscope
Description: intubation with the standard Macintosh laryngoscope and endotracheal tube 7.0 internal diameter with standard tube stylet
Study NCT04363775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Vie Scope laryngoscope
Description: intubation with the Vie Scope laryngoscope with bougie stylet and endotracheal tube 7.0 internal diameter
Study NCT04242082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GLUT 1 gene expression
Description: GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment.
Study NCT04213612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin, cyclophosphamide, vincristine,
Description: PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity
Study NCT02776488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate
Description: Infusion of exogenous sodium lactate
Study NCT02776488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of normal saline
Study NCT00464334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
Study NCT00464334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
Study NCT02871908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri DSM 17938 twice daily 2 x 10\^8
Study NCT02871908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06201806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test food breakfast with NCS or witout NCS
Description: Study Intervention: 30 drops (70.8 mg) of a stevia and sucralose mix were chosen based on Ford et al. 2011, indicating a 48 mg sucralose concentration comparable to the sweetness of a standard diet soda, due to a lack of studies on the acute effects of combined non-nutritive sweeteners.~Glycemic Responses (GR): Blood samples collected using Accu-Chek® Instant glucometer, with fasting samples establishing baseline glucose concentration. Test breakfast or white bread consumed within 12 to 15 minutes, followed by capillary blood sampling at various intervals. Continuous glucose monitoring with a sensor was also implemented.~Glycemic Index (GI) Calculation: Geometric calculation of the area under the curve (AUC) for each food, excluding the baseline area. Test breakfast GI determined by expressing AUC as a percentage of the standard food AUC. Final GI value averaged across groups.
Study NCT06201806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test food breakfast with NCS or witout NCS
Description: Study Intervention: 30 drops (70.8 mg) of a stevia and sucralose mix were chosen based on Ford et al. 2011, indicating a 48 mg sucralose concentration comparable to the sweetness of a standard diet soda, due to a lack of studies on the acute effects of combined non-nutritive sweeteners.~Glycemic Responses (GR): Blood samples collected using Accu-Chek® Instant glucometer, with fasting samples establishing baseline glucose concentration. Test breakfast or white bread consumed within 12 to 15 minutes, followed by capillary blood sampling at various intervals. Continuous glucose monitoring with a sensor was also implemented.~Glycemic Index (GI) Calculation: Geometric calculation of the area under the curve (AUC) for each food, excluding the baseline area. Test breakfast GI determined by expressing AUC as a percentage of the standard food AUC. Final GI value averaged across groups.
Study NCT00464334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to V950
Study NCT03006510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemia prediction alert
Description: In real time, for a patient with a glucose \<90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is >35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia.
Study NCT02393729 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assessment
Description: The neuropsychological assessment will include an assessment of:~* Intellectual ability~* Laterality~* Reading Skills~* Motor skills~* Oral Language~* Attention~* Child's behaviour
Study NCT02393729 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI Study
Description: It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~* Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~* Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task).
Study NCT03620864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Control Exercises
Description: Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
Study NCT02182687 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
Study NCT02182687 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trans-Arterial Chemoembolization (TACE)
Description: First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.
Study NCT02182687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubin
Description: This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
Study NCT02154386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge preservation using DFDBA
Description: tooth extraction followed by ridge preservation grafting using DFDBA
Study NCT02154386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ridge preservation using DFDBA
Description: tooth extraction followed by ridge preservation grafting using DFDBA
Study NCT03002155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EnhanceFitness community exercise program
Description: Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
Study NCT03183193 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (\<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).
Study NCT03183193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLiO diet
Description: The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
Study NCT03837470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium Chloride
Description: Intravenous infusion of 0.25ml/kg/min of 0.9% sodium chloride intravenously for a total of 60 minutes
Study NCT03837470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Bolus intravenous injection of 40 mg furosemide
Study NCT02705651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin-Analog
Description: A long-acting somatostatin-analog will be applied.
Study NCT00520364 — intervention group
Intervention type: OTHER
Intervention: Observation of IVF outcomes in relation to chemo history and AMH
Description: Women undergoing IVF with or without history of chemotherapy, AMH levels compared